For many nonpregnant adults with type 2 diabetes, an A1C goal below 7% is commonly used, but the right target depends on age, health conditions, medications, and hypoglycemia risk. A1C reflects average blood glucose over about 3 months; 6.5% or higher is in the diabetes range for diagnosis 1.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →| A1C result | Common meaning | What it may mean next |
|---|---|---|
| Below 5.7% | Normal range | Usually not in the diabetes or prediabetes range, but your clinician may still check other risks. |
| 5.7% to 6.4% | Prediabetes range | Higher values in this range are linked with higher future diabetes risk; lifestyle and weight-related care may help some people. |
| 6.5% or higher | Diabetes range | A clinician may repeat the test or use another blood glucose test to confirm diagnosis if you do not have clear symptoms. |
| Around or above your personal goal | Needs context | For people already diagnosed, this may mean your care plan needs review, not that one number tells the whole story. |
What does an A1C chart show for type 2 diabetes?
A1C charts show how your hemoglobin A1C percentage maps to normal, prediabetes, and diabetes ranges. They also help people with type 2 diabetes compare a lab result with everyday glucose readings.
A1C measures how much glucose is attached to hemoglobin, the oxygen-carrying protein in red blood cells. Because red blood cells live for roughly 3 months, A1C gives a longer view than one finger-stick glucose result or one continuous glucose monitor, or CGM, reading 1.
A finger-stick glucose, CGM value, fasting plasma glucose, oral glucose tolerance test, and random plasma glucose each answer a different question. A1C is helpful for trends, but it can miss daily highs, lows, and glucose swings that matter for symptoms and safety 3. For more on day-to-day numbers, see our guide to type 2 diabetes blood sugar levels.
What are the A1C ranges for normal, prediabetes, and diabetes?
A1C ranges are commonly grouped as below 5.7%, 5.7% to 6.4%, and 6.5% or higher. These ranges are reference points, not a diagnosis by themselves.
A1C below 5.7%
An A1C below 5.7% is considered in the normal range for diagnosis. It does not guarantee that every glucose reading is normal, especially if you have symptoms, use medications that affect glucose, or have high-risk health factors 1.
A1C 5.7% to 6.4%
An A1C from 5.7% to 6.4% is in the prediabetes range. In a systematic review, people with higher A1C values within this range had a higher future risk of developing diabetes, though individual risk varies 4. If this is your range, our articles on what insulin resistance means and prediabetes treatment may help you prepare for a clinician visit.
A1C 6.5% or higher
An A1C of 6.5% or higher is in the diabetes range. If you do not have clear symptoms of diabetes, NIDDK notes that repeat testing on a different day may be needed to confirm diagnosis 1.
What should my A1C be if I have type 2 diabetes?
For many nonpregnant adults with type 2 diabetes, a target below 7% is commonly used. A safer target may be higher or lower depending on your life stage, health history, and risk of hypoglycemia.
The American Diabetes Association describes person-centered care for type 2 diabetes. Treatment choices may consider heart disease, kidney disease, hypoglycemia risk, weight effects, side effects, cost, and patient preferences 2.
- A less strict A1C goal may be safer for some older adults, people with serious illness, people with a history of severe hypoglycemia, or people taking medications that can cause low blood sugar 2.
- A lower goal may be considered for some people if it can be reached safely without significant hypoglycemia or treatment burden 2.
- Pregnancy, kidney disease, cardiovascular disease, medication side effects, and diabetes distress can all change the safest plan 2, 5.
A1C to average glucose chart: what does your number mean day to day?
Estimated average glucose, or eAG, converts an A1C percentage into the same mg/dL units many home meters and CGMs use. It is an estimate, not a perfect match for every day.
| A1C | Estimated average glucose (eAG) | Plain-English meaning |
|---|---|---|
| 5.7% | About 117 mg/dL | Lower end of the prediabetes range |
| 6.0% | About 126 mg/dL | Prediabetes range |
| 6.5% | About 140 mg/dL | Diabetes range for diagnosis |
| 7.0% | About 154 mg/dL | Common goal area for many adults with type 2 diabetes |
| 8.0% | About 183 mg/dL | Above goal for many adults; needs clinician context |
| 9.0% | About 212 mg/dL | Often signals a need to review the care plan |
| 10.0% | About 240 mg/dL | High average glucose; contact a clinician promptly |
The ADA’s eAG calculator is based on the ADAG study relationship between A1C and average glucose 6. A1C can still hide highs and lows: two people can have the same A1C, while one has steadier glucose and the other has large spikes and drops 3. If you use a CGM, our guide to glucose levels for type 2 diabetes explains how time-in-range and patterns add context.
Is there a “stroke level” A1C?
There is no single stroke level A1C. Stroke risk is shaped by many factors, including blood pressure, cholesterol, smoking, kidney disease, atrial fibrillation, and long-term glucose control.
Long-term high glucose is linked with blood vessel complications of diabetes, including cardiovascular disease, diabetic kidney disease, neuropathy, and diabetic retinopathy 2, 7. But an A1C number alone does not tell you whether a stroke is about to happen.
What A1C is no longer diabetic?
An A1C below 6.5% is below the diabetes diagnostic range, but it does not always erase a diabetes history. Diagnosis, remission, and good control are related, but they are not the same thing.
If your A1C improves, your clinician may describe your diabetes as well controlled or, in some cases, in remission. Medication changes should be clinician-guided because stopping or reducing medication can lead to hyperglycemia, and some drugs carry hypoglycemia risk if not adjusted safely 2.
Why can A1C results be misleading for some people?
A1C results can be misleading when red blood cells or hemoglobin do not behave in the usual way. That is why a clinician may compare A1C with other glucose tests.
- Anemia, hemoglobin variants, recent blood loss, kidney disease, liver disease, or recent transfusion may affect A1C accuracy 1.
- Point-of-care A1C tests can be useful for monitoring, but diagnosis should use an appropriate laboratory method, such as an NGSP-certified laboratory method 1.
- Fasting plasma glucose, oral glucose tolerance testing, random plasma glucose, CGM data, or home glucose meter logs may add important context 1.
What helps improve A1C in type 2 diabetes?
Improving A1C usually means reducing average glucose safely over time. The strongest plans often combine nutrition, activity, weight-related care when needed, medication review, and realistic follow-up.
Practical steps often include higher-fiber meals, fewer sugary drinks, consistent protein, walking or resistance training, sleep support, and medication plans that match the person’s risks. For people with excess weight or insulin resistance, weight loss can improve glucose control, though results vary and the safest approach depends on the person 2. Our guide to weight loss and diabetes explains when weight loss is helpful and when it can be a warning sign.
Clinicians may consider several medication categories, including metformin, GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists, SGLT2 inhibitors, insulin, and others. Medication burden matters too: a randomized study published in 2026 examined medication regimen complexity and diabetes distress, underscoring that care plans should be manageable as well as effective 5.
Ozempic — semaglutide — is a GLP-1 receptor agonist FDA-approved for type 2 diabetes and is not offered by Chia as branded Ozempic. Wegovy — semaglutide — is FDA-approved for chronic weight management and is not offered by Chia as branded Wegovy. Rybelsus — oral semaglutide — is FDA-approved for type 2 diabetes and is not offered by Chia. Mounjaro — tirzepatide — is a dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and is not offered by Chia as branded Mounjaro; Zepbound — tirzepatide — is FDA-approved for chronic weight management and is not offered by Chia as branded Zepbound.
3-min quiz
Considering weight-loss care alongside your diabetes plan?
Chia offers clinician-reviewed weight-loss care for eligible patients with compounded semaglutide injection and compounded tirzepatide tablets or injections. A licensed US provider reviews your health history and prescribes only when clinically appropriate; a prescription is never guaranteed. Compounded drugs are not FDA-approved.
Weight-loss treatment and A1C-related goals at Chia
At Chia, GLP-1 and GIP/GLP-1 weight-loss care may fit some eligible patients with weight-related goals, including people who also have insulin resistance or type 2 diabetes. Chia does not diagnose diabetes, set your personal A1C goal, replace your primary diabetes clinician, or provide emergency care.
We offer compounded semaglutide as an injection, with plans currently starting at $249/mo. We also offer compounded tirzepatide as tablets or injections, with tablet plans currently starting at $249/mo and injection plans currently starting at $299/mo. Microdosing plans are available when clinically appropriate for semaglutide and tirzepatide.
| Chia option | Forms offered | Current starting price | Where it may fit |
|---|---|---|---|
| Compounded semaglutide | Injection | From $249/mo | Weight-loss care for eligible patients after licensed-provider review |
| Compounded tirzepatide | Tablets or injection | Tablets from $249/mo; injection from $299/mo | Weight-loss care for eligible patients; microdosing plans may be considered when appropriate |
| Weight + Energy protocol | NAD+ injection + choice of GLP-1 | From $309/mo | For eligible patients whose goals include weight and energy support, after clinician review |
Treatment at Chia is 100% online: you complete a short health questionnaire, then a licensed US provider reviews it. If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. You can message your care team through the patient portal between visits.
If you have diabetes, keep your diabetes clinician involved. A1C monitoring, kidney screening, eye exams for diabetic retinopathy, foot care, hypoglycemia planning, and medication changes need ongoing medical care beyond weight-loss prescribing 2, 7.
How often should A1C be checked in type 2 diabetes?
Many people with type 2 diabetes have A1C checked at least twice per year when stable and more often when treatment changes or goals are not being met. Your clinician may choose a different schedule.
NIDDK describes A1C as the primary test used for diabetes management after diagnosis 1. You usually do not need to fast for an A1C test, but your clinician may order fasting glucose, cholesterol, kidney tests, or other labs at the same visit.
When should you contact a clinician about your A1C?
Contact a clinician when an A1C result is new, unexpected, above your personal goal, or does not match your home glucose readings. Also reach out if you have symptoms or medication side effects.
- A new A1C of 6.5% or higher should be discussed with a clinician for diagnosis and confirmation testing 1.
- An A1C above your personal goal may mean nutrition, activity, medications, sleep, stress, or weight-related care needs review 2.
- Symptoms of very high blood sugar can include frequent urination, thirst, blurry vision, fatigue, nausea, or unintentional weight loss 1.
- Symptoms of hypoglycemia can include shakiness, sweating, confusion, weakness, fast heartbeat, or fainting; severe symptoms need urgent care 2.
- Rapid weight change, vomiting, dehydration, or new medication side effects should be addressed promptly.
3-min quiz
Start with a clinician-reviewed plan
If your goal is weight-loss care alongside your existing diabetes plan, Chia can review eligibility online for compounded GLP-1 treatment options. Chia’s care does not replace your primary care clinician, endocrinologist, A1C monitoring, or emergency services. Prescriptions require medical evaluation and are not guaranteed; compounded medications are not FDA-approved.
FAQ
For many nonpregnant adults with type 2 diabetes, a goal below 7% is commonly used. Your personal goal may be higher or lower based on age, pregnancy status, kidney disease, heart disease, medications, and hypoglycemia risk.
The main idea is individualized care. A1C goals and medications should be chosen with a clinician based on overall health, glucose patterns, side effects, hypoglycemia risk, weight effects, cost, and what the person can safely manage.
There is no single A1C number called a stroke level. Stroke risk depends on many factors, including blood pressure, cholesterol, smoking, heart rhythm, kidney disease, and long-term glucose control. Stroke symptoms need emergency care no matter what the A1C is.
An A1C below 6.5% is below the diabetes diagnostic range, but it does not always remove a prior diabetes diagnosis. A clinician may describe this as good control or, in some cases, remission. Do not stop or change medication without medical guidance.
An A1C around 7% is near the common goal used for many nonpregnant adults with type 2 diabetes. It may be too high for some people and too low for others if it increases hypoglycemia risk.
Yes. A1C is an average, so it can miss short highs and lows. CGM data, meter readings, fasting glucose, or an oral glucose tolerance test may show patterns that A1C does not capture.
Usually no. A1C does not require fasting. If your clinician orders other labs at the same time, such as fasting glucose or cholesterol, you may be asked to fast for those tests.
Weight loss can improve glucose control for some people with excess weight or insulin resistance, but results vary. Chia offers compounded semaglutide injection and compounded tirzepatide tablets or injections for eligible weight-loss patients after clinician review; compounded drugs are not FDA-approved.
References
- 1.National Institute of Diabetes and Digestive and Kidney Diseases. The A1C Test & Diabetes. NIDDK; 2024.
- 2.American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- 3.American Diabetes Association. Understanding A1C. American Diabetes Association; 2024.
- 4.Zhang X, Gregg EW, Williamson DF, et al. A1C Level and Future Risk of Diabetes: A Systematic Review. Diabetes Care. 2010.
- 5.Teo KM, Shaw RJ, Alexopoulos AS, et al. Comparing the Effects of Diabetes-Specific and Overall Medication Regimen Complexity on Diabetes Distress. The Science of Diabetes Self-Management and Care. 2026.
- 6.Nathan DM, Kuenen J, Borg R, et al. Translating the A1C Assay Into Estimated Average Glucose Values. Diabetes Care. 2008.
- 7.Webb EM, Rheeder P, Roux P. Screening in Primary Care for Diabetic Retinopathy, Maculopathy and Visual Loss in South Africa. Ophthalmologica. 2016.
- 8.Phillips LS, Barb D, Yong C, et al. Translating What Works: A New Approach to Improve Diabetes Management. Journal of Diabetes Science and Technology. 2015.
- 9.Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0-mg Weekly Dose of Semaglutide for Diabetes. Journal of Health Economics and Outcomes Research. 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
